An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.
By Roger Longman
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
